Fig. 2From: Platelets, diabetes and myocardial ischemia/reperfusion injuryTarget of oral anti-aggregant drugs in platelets: thienopyridine (clopidogrel and prasugrel) and non-thienopyridine (ticagrelor and cangrelor) directly or indirectly inhibit ADP receptor P2Y12, thus limiting adenylate cyclase inhibition and platelet aggregationBack to article page